Vibose
Generic Name
Voglibose
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vibose 03 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Vibose 0.3 mg Tablet contains Voglibose, an alpha-glucosidase inhibitor, used to manage postprandial blood glucose levels in patients with type 2 diabetes mellitus. It delays the digestion and absorption of carbohydrates in the small intestine, thereby reducing the rise in blood glucose after meals.
Uses & Indications
Dosage
Adults
Usually 0.2 mg or 0.3 mg, taken three times daily immediately before each main meal. Dosage may be adjusted based on blood glucose response.
Elderly
No specific dose adjustment required, but cautious use is advised.
Renal_impairment
Use with caution in severe renal impairment, as data are limited. Not recommended if creatinine clearance < 25 ml/min.
How to Take
Take orally, immediately before each main meal (breakfast, lunch, and dinner). Do not chew or crush the tablet.
Mechanism of Action
Voglibose competitively inhibits alpha-glucosidase enzymes (sucrase, maltase, isomaltase, glucoamylase) in the brush border of the small intestine. This action delays the digestion of complex carbohydrates into monosaccharides, thus delaying and reducing postprandial glucose absorption.
Pharmacokinetics
Onset
Within 1-2 hours of administration, peak effect after meals.
Excretion
Mainly excreted unchanged in feces (over 99%). Small amount absorbed is renally excreted.
Half life
Short, around 1-2 hours for the small amount absorbed.
Absorption
Poorly absorbed from the gastrointestinal tract (less than 0.2% orally administered dose). Primarily acts locally in the intestine.
Metabolism
Minor metabolism, mainly by intestinal bacteria. Not significantly metabolized by hepatic enzymes.
Side Effects
Contraindications
- •Hypersensitivity to voglibose or any component of the formulation.
- •Diabetic ketoacidosis.
- •Severe infection, trauma, or surgery.
- •Severe renal or hepatic impairment.
- •Chronic intestinal disease associated with marked disorders of digestion or absorption (e.g., inflammatory bowel disease, colonic ulceration).
- •Conditions that may worsen due to increased gas formation in the intestine (e.g., large hernia, intestinal obstruction).
- •Pregnancy and lactation.
Drug Interactions
Thiazolidinediones
No significant interaction reported.
Intestinal adsorbents
May reduce the effect of voglibose.
Sulfonylureas/Insulin
Increased risk of hypoglycemia (dose adjustment may be needed).
Digestive enzyme preparations
May reduce the effect of voglibose.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include flatulence, abdominal distention, and diarrhea. Treatment is symptomatic and supportive. Activated charcoal may be considered. No specific antidote.
Pregnancy & Lactation
Not recommended during pregnancy and lactation due to insufficient data on safety and potential risks. Consult a doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Pharmacies, Hospitals
Approval Status
Approved in many countries including Bangladesh, India, Japan.
Patent Status
Generic available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
